Mopivabil

Cat. No.: HY-145611

Molecular Formula: $C_{14}H_{20}O_3$

Molecular Weight: 236.31

Target: Angiotensin Receptor

Pathway: GPCR/G Protein

Storage:

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (423.17 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	4.2317 mL	21.1586 mL	42.3173 mL
5 mM	0.8463 mL	4.2317 mL	8.4635 mL
10 mM	0.4232 mL	2.1159 mL	4.2317 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

BIOLOGICAL ACTIVITY

Description Mopivabil is the antagonist of angiotensin II receptor[1].

IC_{50} & Target angiotensin II receptor[1]

REFERENCES

[1]. WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA